SciELO - Scientific Electronic Library Online

 
vol.21 número1Accuracy of sacroiliac joint (SIJ) bone scintigraphy in the diagnosis of sacroiliitis in a Colombian cohort with spondyloarthritis (SpA)Characterization of health-related quality of life studies in people with psoriasis: Systematic review 2003-2013 índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Revista Colombiana de Reumatología

versão impressa ISSN 0121-8123

Resumo

VEGA MIRANDA, Juliana et al. Infections in rheumatoid arthritis patients: Biological therapy versus disease modifying anti-rheumatic drugs: One year follow-up. Rev.Colomb.Reumatol. [online]. 2014, vol.21, n.1, pp.27-34. ISSN 0121-8123.

Background: Disease modifying anti-rheumatic drugs and biological disease modifying drugs are used to control inflammation and prevent progression of joint damage in rheumatoid arthritis. It is still controversial whether these drugs increase the incidence of infection in this disease. Methods: A retrospective cohort study was conducted on a population sample of 383 inpatients and outpatients from a university hospital and referral rheumatology tertiary hospital complex in northwestern Colombia. They were classified according to American College of Rheumatology 1987 classification criteria, with 83 in the biological therapy group, and 300 in the disease modifying antirheumatic drugs group, in order to establish the incidence and risk factors for serious and non-serious infections at 12 months follow-up. Results: The majority were females (85%). The biological therapy group presented a greater risk for non-serious [HR 1.73 (95% CI 1.07-2.77; P=.023)] and serious infections [HR 2.56 (95% CI 1.09-6.01; P=.030)]. This finding remained when adjusting for other variables associated with infection (number of disease modifying antirheumatic drugs received, methotrexate, leflunomide and steroids use, diabetes mellitus), with HR for non-serious infection [(1.67, 95% CI 1.05-2.70; P=.030)], and HR for serious infection [(2.67, 95% CI 1.12-6.34; P=.026)]. Chronic lung disease [HR 5.11 (95 % CI 1.18-22.08; P=.029)] was an additional risk factor for serious infections. Conclusions: Biological therapy increases the risk of serious and non-serious infections at 12 months, compared to disease modifying drugs, in a group of patients with rheumatoid arthritis. The risk of serious infections also increases with the presence of chronic lung disease.

Palavras-chave : Arthritis rheumatoid; Biological therapy; Antirheumatic agents.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )